Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Dana-Farber researchers have shown that the mutated copy of the gene TP53 sabotages the normal, healthy copy.
First KRAS targeted therapy shows promise for lung and colon cancer
Both have tested positive for the BRCA2 gene mutation.
New study tests ability of natural language processing to search lung cancer patients’ records for treatable mutations.
Q&A: Riki Peters, PhD, MPH, on what this large genome-wide association study means for patients and the public
Tafinlar plus Mekinist shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
The FDA recently approved Vitrakvi for all cancers with specific gene mutation.
The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.
As mutations occur, a cell may gain the ability to grow without restraint and invade nearby tissue— to become, in effect, a cancer cell.
Turns out mutations in the TP53 gene are focused on so-called “hot spots” because specific carcinogens target those spots.
Cancer geneticists, epidemiologists and oncologists team up to use mutation rate to predict individual cancer risk.
“It stands to reason that we should develop treatments specifically for appendix cancer.”
Novel technique lets researchers control common cancer pathway in the lab with pulses of light.
Findings on nearly 4,000 BRCA1 mutations will be immediately useful to many patients with previously inconclusive genetic test results.
New target identified in glioblastoma could be effective against a common immortality mechanism in one third of cancers.
Fred Hutch researcher zeroes in on biomarkers to better predict aggressive form of the disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.